• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mimetas lands $21m for organ-on-a-chip tech

April 11, 2018 By Sarah Faulkner

MimetasMimetas said today that it raised $20.5 million in a Series B round from a syndicate of investors in Asia and Europe.

The Netherlands-based company intends to use its newly-acquired funds to support global commercialization efforts for its OrganoPlate organ-on-a-chip drug-testing platform.

Mimetas added that it hopes to broaden its product portfolio and establish tissue production facilities, as well as expand into the personalized medicine market.

Investors who contributed to the round included the European Life Sciences Growth Fund, InnovationQuarter, Aglaia Oncology Fund II and Cathay Venture.

“From the start, we were impressed by Mimetas’ technology and highly talented team,” fund manager Ginger Hsiao said in prepared remarks. “We consider the company as today’s leader in the organ-on-a-chip space with tremendous growth potential in the coming years. Its customer base already includes leading multinationals from Europe, US and Asia and the adoption of the platform ranges from academic users to high-throughput screening facilities for pharmaceuticals.”

“This strong investor base ticks all the boxes for Mimetas in this phase of corporate development,” founders Jos Joore and Paul Vulto added. 

Last year, Mimetas touted an organ-on-a-chip system that it developed in collaboration with Roche (OTC:RHHBY) that was designed to evaluate intestinal permeability in 3D gut tubules following exposure to drug compounds.

The researchers reported that the intestinal tubules were leak-tight after just four days in culture and that they expressed specific transporters and receptors. The team’s gut model could be used to assess drug toxicology and to study diseases relating to the intestinal barrier.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Research & Development Tagged With: mimetas

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS